

**Memorial Sloan Kettering Cancer Center (MSK)  
and Weill Cornell Medicine (WCM) Curriculum Vitae**

**Name: Sham Mailankody**

**Signature:**

**Date of Preparation: July 22, 2021**

**A. PERSONAL DATA**

Office address:	530 East 74 <sup>th</sup> Street, New York NY 10021
Office telephone:	646-608-3712
Office fax:	929-321-8155
Home address:	425 Main Street Apt 7E, New York NY 10044
Cell phone:	347-515-2821
Email address - Work:	mailanks@mskcc.org
Email address - Personal:	shambhatm@gmail.com
Is your eligibility to work in the U.S. based on an employment visa?:	Yes
If yes, please provide Visa type (Example: J-1, H-1B, E-3, TN, etc.):	O-1

**B. EDUCATION**

**Academic Degree(s) (*Bachelor's and higher*)**

<b>Degree (include field of study)</b>	<b>Institution name &amp; Location</b>	<b>Dates attended</b>	<b>Year Awarded</b>
MBBS	K S Hegde Medical Academy, Mangalore, India	2001-2007	2008

**Other Education Experiences**

<b>Description</b>	<b>Institution Name &amp; Location</b>	<b>Dates attended</b>
N/A		

**C. POSTDOCTORAL TRAINING (*Include residency/fellowships*)**

<b>Title (include area of training)</b>	<b>Institution name &amp; Location</b>	<b>Dates</b>
Internal Medicine Residency	Georgetown U/Washington Hospital Center, Washington, D.C.	2009 - 2012
Medical Oncology and Hematology Fellowship	National Cancer Institute, National Institutes of Health Bethesda, MD	2012 - 2015

**D. PROFESSIONAL POSITIONS & EMPLOYMENT****Academic Appointments**

<b>Title</b>	<b>Institution, city and state</b>	<b>Dates</b>
Assistant Member (Level 1)	Memorial Sloan Kettering Cancer Center, New York, NY	2015 - 2018
Instructor in Medicine	Weill Cornell Medical College, New York, NY	2015 - 2018
Assistant Member	Memorial Sloan Kettering Cancer Center, New York, NY	03/18 - current
Assistant Professor of Medicine	Weill Cornell Medical College, New York, NY	03/18 - current

**Hospital Appointments**

<b>Title</b>	<b>Institution, city and state</b>	<b>Dates</b>
Assistant Attending Physician	Memorial Hospital for Cancer and Allied Diseases, New York, NY	2015 - current

**Other Professional Positions & Employment**

<b>Title</b>	<b>Institution, city and state</b>	<b>Dates</b>
Locum Tenens	AJ Institute of Medical Sciences, Mangalore, India	06/07 - 05/08
Clinical Observership	Southern Illinois University, Springfield, IL	05/08 - 06/08
Research Assistant	Mayo Clinic, Rochester, NY	07/08 - 07/08
Research & Clinical Observership	Massachusetts General Hospital, Boston, MA	08/08 - 09/08
Vacation	N/A	10/08 – 10/08
Residency Application and Interviews	N/A	11/08 – 12/08
Research Assistant	Mayo Clinic, Rochester, NY	12/08 - 02/09
Vacation	N/A	03/09 – 06/09

**E. LICENSURE, BOARD CERTIFICATION****Licensure:**

<b>State</b>	<b>Number</b>	<b>Date of issue</b>	<b>Date of Expiration</b>
New York	279162	04/07/2015	10/31/2022
New Jersey	N/A		

<b>DEA number:</b> (optional)	FM5556521
<b>NPI number:</b> (optional)	1912235946

## Board Certification

Full Name of Board	Certificate # <i>(indicate if board eligible)</i>	Dates of Certification
American Board Of Internal Medicine, Internal Medicine	328313	2012 - 2022
American Board Of Internal Medicine, Medical Oncology	328313	2015 - 2025

## F. INSTITUTIONAL/HOSPITAL AFFILIATION

Primary Hospital Affiliation:	Memorial Hospital for Cancer and Allied Diseases
Other Hospital Affiliations:	N/A
Other Institutional Affiliations:	Weill Cornell Medical College

## G. EMPLOYMENT STATUS

Name of Current Employer(s):	Memorial Sloan Kettering Cancer Center
Current Employment Status:	- Full-time salaried by MSK

## H. HONORS, AWARDS

<b><i>Name of award</i></b>	<b><i>Organization</i></b>	<b><i>Date awarded</i></b>
Late P Vittal Shetty Prize for Top Scorer in Pediatrics examination	K S Hegde Medical Academy	2007
Dr V R Bhat Prize for Top Scorer in General Medicine examination	K S Hegde Medical Academy	2007
Smt. Mani Bai and Sri B Sidda Naik Gold Medal for Top Scorer in Medicine	Rajiv Gandhi University of Health Sciences	2008
Dr H.B. Rajashekar gold medal for the best outgoing student in Medicine	Rajiv Gandhi University of Health Sciences	2008
Best Intern of the year	Georgetown University/Washington Hospital Center	2010
Best Resident of the year	Georgetown University/Washington Hospital Center	2012
Saul Zuckerman Humanitarianism in Medicine Award	Georgetown University/Washington Hospital Center	2012
Herb Kotz Exemplary Oncologist Award	National Cancer Institute, NIH	2013

**I. PROFESSIONAL ORGANIZATIONS AND SOCIETY MEMBERSHIPS***(Please include medical and scientific societies.)*

<b>Organization</b>	<b>Date</b>
American Society of Clinical Oncology	2015 - current
American Society of Hematology	2018 - current

**J. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES**

<b>MSK Activity</b>	<b>Percent Effort (%)</b>	<b>Does the activity involve MSK students/research trainees? (Yes/No)</b>	<b>Does the activity involve WCM students/research trainees? (Yes/No)</b>
Teaching	10%	Yes	Yes
Clinical	40%	Yes	Yes
Administrative	10%	No	No
Research	40%	No	No
<b>Total</b>	<b>100%</b>		

**K. EDUCATIONAL CONTRIBUTIONS****Teaching****Didactic teaching**

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
Thinking Like an Oncologist	Clinical Fellows	02/04/2021
First Year Fellows Core Lecture Series	Clinical Fellows	03/01/2021
Resident Noon Conference	Clinical Residents	1/14/2021
Resident Noon Conference	Clinical Residents	2/11/2021

**Clinical teaching**

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
N/A		

**Administrative teaching**

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
N/A		

**Continuing education and professional education as teacher**

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
N/A		

**Community education or patient outreach**

<i>Title</i>	<i>Audience</i>	<i>Dates</i>
N/A		

**L. CLINICAL PRACTICE, INNOVATION, and LEADERSHIP**

**Clinical Practice**

<i>Duration</i>	<i>Name/Location of Practice</i>	<i>Type of Activity</i>	<i>Level of Activity</i>
1-2 days per week	Myeloma Clinic, Memorial Sloan Kettering Cancer Center	Ambulatory Practice	Attending
0.5 days per week	Cell Therapy Clinic, Memorial Sloan Kettering Cancer Center	Ambulatory Practice	Attending
4-6 weeks per year	Myeloma Service, Memorial Sloan Kettering Cancer Center	Inpatient unit	Attending

**Clinical Innovations**

<i>Date Innovation Launched</i>	<i>Title/Location of Innovation</i>	<i>Role</i>	<i>Short Description of the influence on clinical care or practice management</i>
N/A			

**Clinical Leadership**

<i>Years</i>	<i>Leadership Role</i>	<i>Short Description of activity/program</i>
N/A		

**M. RESEARCH**

My research focuses on two broad areas- 1) Clinical and translational research focused on cellular and other immunotherapeutic approaches for the treatment of multiple myeloma, 2) Health services research focused on the clinical effectiveness, trial participation, and outcomes for patients with cancer diagnosis.

The primary focus is on the development of early stage trials of novel CAR T therapies for multiple myeloma. I am the principal investigator of several first in human investigator initiated and sponsored trials in this area and the national lead for multicenter trials of CART therapies for multiple myeloma.

**Research Activities:**

<i>List IRB protocols (both active and inactive: IRB #, title, dates start-end or start- if ongoing, PI, and your role)</i>
15-294: MLN9708 and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study, 12/15 – 06/19, Role: Principal Investigator
17-025: A phase I trial of B-cell maturation antigen (BCMA)-targeted EGFRt/BCMA-41BBz chimeric antigen receptor (CAR) modified T cells with and without lenalidomide for the treatment of multiple myeloma, 03/17 – 01/18, Role: Principal Investigator
18-043: An open-label Phase I/II Study of JCARH125, BCMA-targeted chimeric antigen receptor (CAR) T cells, in subjects with relapsed or refractory multiple myeloma, 01/18 – 03/21, Role: Principal Investigator
18-048: Short course daratumumab in minimal residual disease (MRD) positive myeloma patients after induction therapy with/without consolidative high dose chemotherapy/autologous stem cell support., 05/18 – current, Role: Principal Investigator
18-367: A Phase I trial of G Protein-coupled receptor class C group 5 member D (GPC5D) targeted MCARH109 chimeric antigen receptor (CAR) modified T cells for the treatment of multiple myeloma, 08/20 – current, Role: Principal Investigator

<i>List IRB protocols (both active and inactive: IRB #, title, dates start-end or start- if ongoing, PI, and your role)</i>	
<i>19-392: A single-arm open-label phase I study of the safety, efficacy, and cellular kinetics/pharmacodynamics of ALLO-715 to evaluate an anti-BCMA allogeneic CAR T cell therapy in subjects with relapsed/refractory multiple myeloma, 11/19 – current, Role: Principal Investigator</i>	
<i>20-310: A phase I multicentre, open-label study of CC-98633, BCMA-targeted NEX-T chimeric antigen receptor (CAR) T cells, in subjects with relapsed and/or refractory multiple myeloma, 09/20 – current, Role: Principal Investigator</i>	

**Research Support:**

**Current Research Funding**

Award Source: (funding agency – federal, foundation, industry; type of grant)*	National Cancer Institute, R21CA235154
Project title:	Linking population-based data sources to examine health disparities in clinical trial participation and outcomes
Name of Principal Investigator:	Allison Snyderman-Lipitz and Sham Mailankody
The major goals of this project are:	The purpose of this proposal is to create a national database that will tell us about older adult patients who have participated in clinical trials. This will allow us to answer questions about what kinds of people participate in these trials, where they are treated, what doctors treat them, and the benefits and risks of such participation, which can influence the future of clinical trials research.

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Bristol Myers Squibb; Preclinical studies
Project title:	To investigate the acute and delayed toxicity of a single intravenous dose of MCARH125 and pooled MCARH109/MCARH125 CAR T Cells in a multiple myeloma mouse model
Name of Principal Investigator:	Sham Mailankody
The major goals of this project are:	To complete pre-clinical toxicology and animal studies to support Investigational New Drug application for concurrent administration to GPRC5D and BCMA targeted CART cells in multiple myeloma.

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Bristol Myers Squibb; Clinical trial
Project title:	A Phase I trial of G Protein-coupled receptor class C group 5 member D (GPRC5D) targeted MCARH109 chimeric antigen receptor (CAR) modified T cells for the treatment of multiple myeloma.
Name of Principal Investigator:	Sham Mailankody
The major goals of this project are:	Ani investigator initiated first in human trial of GPRC5D targeted CART therapy in relapsed or refractory multiple myeloma.

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Janssen Oncology; Clinical trial
Project title:	Short Course Daratumumab in Minimal Residual Disease (MRD) Positive Myeloma Patients After Induction Therapy

	With/Without Consolidative High Dose Chemotherapy/Autologous Stem Cell Support
Name of Principal Investigator:	Sham Mailankody
The major goals of this project are:	An investigator-initiated trial of short course daratumumab in multiple myeloma patients with MRD positivity

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Bristol Myers Squibb; Clinical trial
Project title:	An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory Multiple Myeloma
Name of Principal Investigator:	Sham Mailankody
The major goals of this project are:	A registration phase I/II trial of JCARH125, a BCMA targeted CART therapy. I am the site PI for this trial.

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Takeda Oncology; Clinical Trial
Project title:	Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
Name of Principal Investigator:	Sham Mailankody
The major goals of this project are:	An investigator initiated pilot trial of early therapy for smoldering myeloma.

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Juno Therapeutics; Clinical Trial
Project title:	A Phase I Trial of B-cell Maturation Antigen (BCMA)-Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T cells for the Treatment of Multiple Myeloma
Name of Principal Investigator:	Sham Mailankody
The major goals of this project are:	An investigator-initiated trial of MCARH171, a BCMA targeted CART therapy.

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Allogene Therapeutics; Clinical Trial
Project title:	A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 and ALLO-647 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy with and without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma
Name of Principal Investigator:	Sham Mailankody
The major goals of this project are:	A multicenter phase I trial of the first allogeneic BCMA CART therapy for multiple myeloma. I am the site PI for this trial.

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Bristol Myers Squibb; Clinical Trial
Project title:	A Phase 1, Multicenter, Open-Label Study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed and/or Refractory Multiple Myeloma

Name of Principal Investigator:	Sham Mailankody
The major goals of this project are:	A multicenter phase I trial of a next generation BCMA CART therapy. I am the site PI for this trial.

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Philanthropy
Project title:	John Riconda Research Fund for Cell Therapy of Multiple Myeloma
Name of Principal Investigator:	Principal Investigator
The major goals of this project are:	Philanthropic support for correlative and translational studies to optimize cellular therapies for multiple myeloma

Award Source: (funding agency – federal, foundation, industry; type of grant)*	MSKCC Center for Experimental Therapeutics
Project title:	Curing Relapsed Refractory Myeloma with Combined Immune Therapies (Project 1: Optimizing CAR T Therapy in RRMM)
Name of Principal Investigator:	Sergio Giralto
The major goals of this project are:	To optimize the use of commercially available BCMA CART therapy idecel in patients with relapsed and refractory multiple myeloma. I am a project PI for this grant.

### Past (Completed) Funding

Award Source: (funding agency – federal, foundation, industry; type of grant)*	
Project title:	
Total direct costs:	
Duration of support:	
Name of Principal Investigator:	
Your percent (%) effort:	
The major goals of this project are:	

### Pending Funding

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Leukemia Lymphoma Society
Project title:	Orphan G protein coupled receptor, class C group 5 member D (GPRC5D) targeted CAR T cell therapy for relapsed or refractory multiple myeloma
Name of Principal Investigator:	Sham Mailankody
The major goals of this project are:	This a career development grant to provide protected time for clinical and translational research. My proposal focuses on developing novel cellular therapies for management of multiple myeloma.

Award Source: (funding agency – federal, foundation, industry; type of grant)*	Fate Therapeutics/Clinical Trial
---	----------------------------------

Project title:	A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma
Total direct costs:	TBD
Duration of support:	06/2021 – 10/2025
Name of Principal Investigator:	Sham Mailankody
Your percent (%) effort:	2%
The major goals of this project are:	This is a phase I trial of FT538 which is a novel iPSC derived NK cell based therapy for treatment for acute leukemia and multiple myeloma. I am the site PI for this trial.

## Patents & Inventions

<i>Inventors</i>	<i>Title of Invention</i>	<i>Patent Number</i>
N/A		

## N. MENTORING

### Current Mentees

Name	Muhammed Turab
Site/Position	Resident, Internal Medicine/University of Connecticut
Expected Period	07/2020 - current
Project/Accomplishments**	Completed a review article that was recently submitted to Seminars in Oncology
Goals/expected Outcomes	Provide necessary guidance and support as he embarks on a career in academic oncology.
Type of Supervision (Research, clinical, teaching, leadership)	Research

Name	Gil Hevroni
Site/Position	Resident, Internal Medicine/SUNY Downstate
Expected Period	07/2020 - current
Project/Accomplishments**	Works in my clinic for 15 weeks in a year
Goals/expected Outcomes	Provide necessary guidance and support as she embarks on a career in academic oncology.
Type of Supervision (Research, clinical, teaching, leadership)	Clinical and Teaching

### Past Mentees:

<i>Name</i>	<i>Rohan Maniar</i>
<i>Site/Position</i>	Resident, Internal Medicine/Weill Cornell Medical College
<i>Mentoring Period</i>	08/2016 – 06/2018
<i>Project/Accomplishments**</i> ,	Completed a project presented at ASCO annual meeting.
<i>Current Position</i>	Clinical Fellow, Columbia University
<i>Type of Supervision (Research, clinical, teaching, leadership)</i>	Research

Name	Tania Jain
Site/Position	Clinical Fellow, MSKCC
Mentoring Period	07/2018 – 06/2019

Project/Accomplishments**,	Hematopoietic recovery in patients receiving CART therapy for hematologic malignancies
Current Position	Assistant Professor, Johns Hopkins University
Type of Supervision (Research, clinical, teaching, leadership)	Research

### Institutional Training Grants and Mentored Trainee Grants

Award Source: (funding agency, type of grant)	N/A
Project title:	
Duration of support:	
Mentee (if applicable):	

### Other mentoring activities Describe activity; indicate dates.

Activity	Dates
N/A	

### O. INSTITUTIONAL LEADERSHIP ACTIVITIES

Role(s)/Position	Institution/Location	Dates

### P. INSTITUTIONAL ADMINISTRATIVE ACTIVITIES

Name of Committee	Role (i.e. member, secretary, chair, etc.)	Dates
MSK Department of Medicine Protocol Development Committee	Member	2016 - 2021
Institutional Biosafety Committee	Member	2021 - current

### Q. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

#### Leadership in Extramural Organizations

Organization	Role (i.e. member, secretary, chair, etc.)	Dates
N/A		

#### Service on Boards and/or Committees

##### Regional

Name of Committee	Role (i.e. member, secretary, chair, etc.)	Organization Institution/Location	Dates
N/A			

**National**

<i>Name of Committee</i>	<i>Role (i.e. member, secretary, chair, etc.)</i>	<i>Organization Institution/Location</i>	<i>Dates</i>
N/A			

**International**

<i>Name of Committee</i>	<i>Role (i.e. member, secretary, chair, etc.)</i>	<i>Organization Institution/Location</i>	<i>Dates</i>
<i>Annual Meeting Education Committee</i>	<i>Member</i>	<i>American Society of Clinical Oncology</i>	<i>2018 - 2019</i>
<i>Annual Meeting Scientific Committee</i>	<i>Member</i>	<i>American Society of Clinical Oncology</i>	<i>2020 - current</i>

**Grant Reviewing/Study Sections**

<i>Role(s)</i>	<i>Organization Name</i>	<i>Dates</i>
N/A		

**Editorial Activities**Journal Reviewing/ad hoc reviewing

<i>Journal / Organization Name</i>	<i>Dates</i>
British Medical Journal	2014 - 2019
JAMA Oncology	2015 - 2020
JAMA	2017 - 2020
JAMA Internal Medicine	2018
New England Journal of Medicine	2018 - 2020
Journal of Clinical Oncology	2018
Clinical Cancer Research	2016

Editor/Co-Editor

<i>Books / Textbooks / Journals / Organization Name</i>	<i>Dates</i>
N/A	

Editorial Board Membership

<i>Board / Organization Name</i>	<i>Dates</i>
Deputy Editor, Seminars in Oncology	2017 - 2018

**R. INVITED AND/OR PEER-SELECTED PRESENTATIONS****Regional**

<i>Title</i>	<i>Institution/Location</i>	<i>Dates</i>
N/A		

**National**

<i>Title</i>	<i>Institution/Location</i>	<i>Dates</i>
Responses to CAR T cell therapy in myeloma	Lymphoma and Myeloma Congress, New York	2019

**International**

<i>Title</i>	<i>Institution/Location</i>	<i>Dates</i>
Can we put a price on progress? Cost and value in myeloma therapy	ASCO Annual Meeting, Chicago	2017

Precision oncology: Clinical promise and regulatory challenges	Frontiers in Cancer Research and Therapy, Stockholm	2018
Cancer costs, trials, and defining value- how to reconcile	Challenges Preventing Cancer Cure, London	2019
Many shades of disparities in myeloma care: Global disparities in myeloma care	ASCO Annual Meeting, Chicago	2019
Immune Effector Cell therapies in Multiple Myeloma Workshop	Boston	2019
ALLO-CAR T therapy in myeloma	International Workshop on CAR-T, virtual meeting	2021
Immune Effector Cell therapies in Multiple Myeloma Workshop	Boston	2021

## S. BIBLIOGRAPHY

### Peer-reviewed Research Articles:

1. Rostambeigi N, Kudva YC, John S, **Mailankody S**, Pedersen RA, Dean PG, Prieto M, Cosio FG, Kremers WK, Walker RC, Abraham RS, Stegall MD. Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantation. *Transplantation* 2010; 89(9): 1126-33. PMID: 20164817.
2. **Mailankody S**, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR, Turesson I, Landgren O. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). *Blood* 2011; 118(15): 4086-92. PMID: 21795746.
3. Landgren O, Thomas A, **Mailankody S**. Myeloma and second primary cancers. *The New England Journal of Medicine* 2011; 365(23): 2241-2. PMID: 22310913.
4. Wu SP, Costello R, Hofmann JN, Korde N, **Mailankody S**, Purdue M, Landgren O. MGUS prevalence in a cohort of AML patients. *Blood* 2013; 122(2): 294-5. PMID: 23847188.
5. Sigurdurdottir EE, Turesson I, Lund SH, Lindqvist EK, **Mailankody S**, Korde N, Bjorkholm M, Landgren O, Kristinsson SY. The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma. *JAMA Oncology* 2015; 1(2): 168-74. PMID: 26181017.
6. Engels EA, Landgren O, Costello R, Burton D, **Mailankody S**, Storek J. Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients. *Bone Marrow Transplantation* 2015; 50(1): 146-7. PMID: 25265459.
7. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tajeja N, Kazandjian D, **Mailankody S**, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping E, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. *JAMA Oncology* 2015; 1(6): 746-54. PMID: 26181891.
8. **Mailankody S**, Prasad V. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. *JAMA Oncology* 2015; 1(4): 539-40. PMID: 26181265. PMID: 26181265.

9. Jonsdottir G, Lund SH, Bjorkholm M, Turesson I, Wahlin A, **Mailankody S**, Blimark C, Hultcrantz M, Porwit A, Landgren O, Kristinsson SY. Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. *Haematologica* 2016; 101(4): e145-8. PMID: 26681760.
10. Bhutani M, Turkbey B, Tan E, Korde N, Kwok M, Manasanch EE, Tajeja N, **Mailankody S**, Roschewski M, Mulquin M, Carpenter A, Lamping E, Minter AR, Weiss BM, Mena E, Lindenberg L, Calvo KR, Maric I, Uzmani S, Choyke PL, Kurdziel K, Landgren O. Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. *Leukemia & Lymphoma* 2016; 57(5): 1114-21. PMID: 26690712.
11. Kumar H, Fojo T, **Mailankody S**. An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials. *JAMA Oncology* 2016; 2(9): 1238-40. PMID: 27281466.
12. Lendvai N, Yee AJ, Tsakos I, Alexander A, Devlin SM, Hassoun H, Korde N, Lesokhin AM, Landau H, **Mailankody S**, Koehne G, Chung DJ, Landgren O, Raje NS, Giralto S. Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma. *Blood* 2016; 127(19): 2355-6. PMID: 27020089.
13. Murata K, McCash SI, Carroll B, Lesokhin AM, Hassoun H, Lendvai N, Korde NS, **Mailankody S**, Landau HJ, Koehne G, Chung DJ, Giralto SA, Ramanathan LV, Landgren O. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. *Clinical Biochemistry* 2016; 51: 66-71. PMID: 27664535.
14. Ogunniyi A, Rodriguez M, Devlin S, Adel N, Landau H, Chung DJ, Lendvai N, Lesokhin A, Koehne G, **Mailankody S**, Korde N, Reich L, Landgren O, Giralto S, Hassoun H. Upfront use of plerixafor and granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiency. *Leukemia & Lymphoma* 2016; 58(5): 1123-1129. PMID: 27735212.
15. Prasad V, Wang R, Afifi SH, **Mailankody S**. The Rising Price of Cancer Drugs-A New Old Problem? *JAMA Oncology* 2016; 3(2): 277-278. PMID: 27711927.
16. Wu SP, Pfeiffer RM, Ahn IE, **Mailankody S**, Sonneveld P, van Duin M, Munshi NC, Walker BA, Morgan G, Landgren O. Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients. *Clinical Cancer Research* 2016; 22(16): 4039-44. PMID: 26847058.
17. Landgren O, Devlin S, Boulad M, **Mailankody S**. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. *Bone Marrow transplant* 2016; 51(12): 1565-68. PMID: 27595280.
18. **Mailankody S**, Devlin SM, Korde N, Lendvai N, Lesokhin A, Landau H, Hassoun H, Ballagi A, Ekman D, Chung DJ, Patel M, Koehne G, Giralto S, Landgren O. Proteomic profiling in plasma cell disorders: a feasibility study. *Leukemia & Lymphoma* 2017; 58(7): 1757-59. PMID: 27908223.
19. Sissung TM, Peer CJ, Korde N, **Mailankody S**, Kazandjian D, Venzon DJ, Landgren O, Figg WD. Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms. *Cancer Chemother Pharmacol* 2017; 80(1): 217-21. PMID: 28488026.
20. Hofmann JN, **Mailankody S**, Korde N, Wang Y, Tajeja N, Costello R, Zingone A, Hultcrantz M, Pollak MN, Purdue MP, Landgren O. Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease. *Obesity* 2017; 25(8): 1317-20. PMID: 28602036.
21. Dosani T, **Mailankody S**, Korde N, Manasanch E, Bhutani M, Tajeja T, Roschewski M, Kwok M, Kazandjian D, Costello R, Burton D, Zhang Y, Liewehr D, Steinberg SM, Maric I, Landgren O. Host-related immunodeficiency in the development of multiple myeloma. *Leukemia & Lymphoma* 2017; 59(5): 1127-1132. PMID: 28792255.

22. Hassoun H, Roshal M, Sabari J, Nguyen J, Gao Q, Devlin SM, Landau H, Lendvai N, Chung DJ, Lesokhin AM, Korde N, **Mailankody S**, Dogan A, Giralt SA, Landgren CO. Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. *Leukemia & Lymphoma* 2017; 58(12):2962-2965. PMID: 28482750.
23. Thordardottir M, Lindqvist EK, Lund SH, Costello R, Burton D, Korde N, **Mailankody S**, Eiriksdottir G, Launer LJ, Gudnason V, Harris TB, Landgren O, Kristinsson SY. Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: A population-based study. *Blood Advances* 2017; 1(24), 2186-2192. PMID: 29296866.
24. Landgren O, Graubard BI, Kumar S, Kyle RA, Katzmann JA, Murata K, Costello R, Dispenzieri A, Caporaso N, **Mailankody S**, Korde N, Hultcrantz M, Therneau TM, Larson DR, Cerhan JR, Rajkumar SV. Prevalence of Myeloma Precursor State Monoclonal Gammopathy of Undetermined Significance in 12372 Individuals 10–49 Years Old: A Population-Based Study from the National Health and Nutrition Examination Survey. *Blood Cancer Journal* 2017; 7(10):e618. PMID: 29053158.
25. Prasad V, **Mailankody S**. Research and development spending to bring a single cancer drug to market and revenues after approval. *JAMA Internal Medicine* 2017; 177(11): 1569-1575. PMID: 28892524.
26. Dreicer J. J, **Mailankody S**, Fahkrejahani F, & Prasad V. Clinically meaningful benefit: Real world use compared against the American and European guidelines. *Blood Cancer Journal* 2017; 7(12): 645. PMID: 29238046.
27. **Mailankody S**, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. *Blood Advances* 2017; 1(22), 1911-1918. PMID: 29296837.
28. Lendvai N, Tsakos I, Devlin S, Schaffer W, Hassoun H, Lesokhin A, Landau H, Korde N1, **Mailankody S**, Smith E, Chung DJ, Koehne G, Shah GL, Alexander A, Patel M, Ballagi A, Grundberg I, Giralt SA, Landgren O. Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. *Leukemia & Lymphoma* 2018; 59(8): 1981-1985. PMID: 29308691.
29. Tageja N, Korde N, Kazandjian D, Panch S, Manasanch E, Bhutani M, Kwok M, **Mailankody S**, Yuan C, Stetler-Stevenson M, Leitman SF, Sportes C, Landgren O. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma. *Bone Marrow Transplantation* 2018; 53(11): 1445-1449. PMID: 29728700.
30. Hayes M. J, Kaestner V, **Mailankody S**, Prasad V. Most medical practices are not parachutes: A citation analysis of practices felt by biomedical authors to be analogous to parachutes. *CMAJ Open* 2018,6(1):E31-E38. PMID: 29343497.
31. Wagner J, Marquart J, Ruby J, Lammers A, **Mailankody S**, Kaestner V, Prasad V. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: Retrospective observational study. *BMJ* 2018; 360:k668. PMID: 29514787.
32. Palazzo M, Shah GL, Copelan O, Seier K, Devlin SM, Maloy M, Kenny S, Hassoun H, Korde NS, Lendvai N, Lesokhin AM, **Mailankody S**, Chung DJ, Koehne G, Landgren CO, Landau H, Giralt SA, Perales MA. Re-immunization following Autologous Hematopoietic Stem Cell Transplantation (Auto HCT) is Safe and

Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. *Biol Blood Marrow Transplant* 2018; 24(4): 871-876. PMID: 29288818.

33. Kazandjian D, Korde N, **Mailankody S**, Hill E, Figg WD, Roschewski M, Landgren O. Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: Five year follow-up of a phase II clinical trial. *JAMA Oncology* 2018; 4(12): 1781-83. PMID: 30477009.
34. Huang PA, Beedie SL, Chau CH, Venzon DJ, Gere S, Kazandjian D, Korde N, **Mailankody S**, Landgren O, Figg DG. Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide. *Science Reports* 2019; 9(1): 14884. PMID: 31619706.
35. Landgren O, Hofmann JN, McShane CM, Santo L, Hultcrantz M, Korde N, **Mailankody S**, Kazandjian D, Murata K, Thoren K, Ramanathan L, Dogan A, Rustad E, Lu SX, Akhlagi T, Kristinsson SY, Bjorkholm M, Devlin S, Purdue MP, Pfeiffer RM, Turesson I. Association of immune markers changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma. *JAMA Oncology* 2019; 5(9): 1293-1301. PMID: 31318385.
36. Smith EL, **Mailankody S**, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF, Geyer MB, Goldberg AD, Mead E, Santamasso BD, Landa J, Rimner A, Riviere I, Landgren O, Brentjens RJ. BCMA-targeted CAR T cell therapy plus radiotherapy for the treatment of refractory myeloma reveal potential synergy. *Cancer Immunology Research* 2019; 7(7): 1047-1053. PMID: 31113804.
37. Kazandjian D, Hill E, Hultcrantz M, Rustad EH, Yellapantula V, Akhlaghi T, Korde N, **Mailankody S**, Dew A, Papemmanuil E, Maric I, Kwok M, Landgren O. Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. *Blood Cancer Journal* 2019; 9(2): 15. PMID: 30718460.
38. Rustad E, Misund K, Bernard E, Coward E, Yellapantula VD, Hultcrantz M, Ho C, Kazandjian K, Korde N, **Mailankody S**, Keats JJ, Akhlaghi T, Viny AD, Mayman DJ, Carroll K, Patel M, Famulare CA, Op Bruinink DH, Hutt K, Jacobsen A, Huang Y, Miller JE, Maura F, Papaemmanuil E, Waage A, Arcila ME, Landgren O. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. *American Journal of Hematology* 2019; 94(12): 1364-1373. PMID: 31571261.
39. Yellapantula V, Hultcrantz, Rustad EH, Wasserman E, Londono D, Cimera R, Ciardiello A, Landau H, Akhlaghi T, **Mailankody S**, Patel M, Medina-Martinez JS, Arango Ossa JE, Levine MF, Bolli N, Maura F, Dogan A, Papemmanuil E, Zhang Y, Landgren O. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. *Blood Cancer Journal* 2019; 9(12):101. PMID: 31827071.
40. Salcedo M, Lendvai N, Mastey D, Schlossman J, Hultcrantz M, Korde N, **Mailankody S**, Lesokhin A, Hassoun H, Smith E, Shah U, Diab V, Werner K, Landau H, Lahoud O, Drullinsky P, Shah G, Chung D, Scordo M, Giral S, Landgren O. Phase I study of selinexor, ixazomib, low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. *Clinical Lymphoma Myeloma Leukemia* 2020; 20(3): 198-200. PMID: 32001193.
41. Eveillard M, Rustad E, Roshal M, Zhang Y, Ciardiello A, Korde N, Hultcrantz M, Lu S, Shah U, Hassoun H, Smith E, Lesokhin A, **Mailankody S**, Landgren O, Thoren K. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flowcytometry for tracking measurable residual disease in patients with multiple myeloma. *British Journal of Haematology* 2020; 189(5): 904-907. PMID: 32026474.
42. Nawar T, Morjaria S, Kaltsas A, Patel D, Perez-Johnston R, Daniyan AF, **Mailankody S**, Parameswaran R. Granulocyte-colony stimulating factor in COVID-19: Is it stimulating more than just the bone marrow? *American Journal of Hematology* 2020; 95(8): E210-E213. PMID: 32419212.

43. Bal S, Landau HJ, Shah GL, Scordo M, Dahi P, Lahoud OB, Hassoun H, Hultcrantz M, Korde N, Lendvai N, Lesokhin AM, **Mailankody S**, Shah UA, Smith E, Devlin SM, Avecilla S, Dogan A, Roshal M, Landgren O, Giralt S, Chung DJ. Stem cell mobilization and autograft minimal residual disease negativity with novel induction regimens in multiple myeloma. *Biology of Blood and Marrow Transplantation* 2020; 26(8): 1394-1401. PMID: 32442725.
44. Hultcrantz M, Richter J, Rosenbaum C, Patel D, Smith E, Korde N, Lu S, **Mailankody S**, Shah U, Lesokhin A, Hassoun, Tan C, Maura F, Derkach A, Diamond B, Rossi A, Pearse RN, Madduri D, Chari A, Kaminetzky D, Braunstein M, Gordillo C, Davies F, Jagannath S, Niesvizky R, Lentzsch S, Morgan G, Landgren O. COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. *Blood Cancer Discovery* 2020; 1:234-243. PMID: 32577667.
45. Landau HJ, Yellapantula V, Diamond BT, Rustad EH, Maclachlan KH, Gundem G, Medina-Martinez J, Ossa JA, Levine MF, Zhou Y, Kappagantula R, Baez P, Attiye M, Makohon-Moore A, Zhang L, Boyle EM, Ashby C, Blaney P, Patel M, Zhang Y, Dogan A, Ching DJ, Giralt S, Lahoud OB, Peled JU, Scordo M, Shah G, Hassoun H, Korde NS, Lesokhin AM, Lu S, **Mailankody S**, Shah U, Smith E, Hultcrantz ML, Ulaner GA, van Rhee F, Morgan GJ, Landgren O, Papaemmanuil E, Iacobuzio-Donahue C, Maura F. Accelerated single cell seeding in relapsed multiple myeloma. *Nature Communications* 2020; 11(1): 3617. PMID: 32680998.
46. Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, Devlin SM, Smith M, Shah GL, Halton E, Diamonte C, Scordo M, Sauter CS, Mead E, Santomaso BD, Palomba ML, Batlevi CW, Maloy MA, Giralt S, Smith E, Brentjens R, Park JH, Perales MA, **Mailankody S**. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. *Blood Advances* 2020; 4(15): 3776-3787. PMID: 32780846.
47. Green AK, Curry M, Trivedi N, Bach PB, **Mailankody S**. Treatment outcomes of Medicare patients receiving newly approved oncology drugs. *JAMA Network Open* 2021; 4(2):e210030. PMID: 33625507.
48. Korde N, Mastey D, Tavitian E, **Mailankody S**, Lesokhin A, Hassoun H, Smith EL, Lendvai N, Hultcrantz M, Shah U, Tan C, Lu S, Diamond B, Salcedo M, Werner K, Chung DJ, Scordo M, Shah GL, Lahoud O, Landau H, Arcila M, Ho C, Roshal M, Dogan A, Derkach A, Devlin SM, Giralt SA, Landgren O. Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup>) in combination with lenalidomide and dexamethasone. *American Journal of Hematology* 2021; 96(6):E193-E196. PMID: 33661527.
49. Nawas MT, Shah GL, Feldman DR, Ruiz JD, Robilotti EV, Aslam AA, Dundas M, Kamboj M, Barker JN, Cho C, Chung DJ, Dahi PB, Giralt SA, Gyurkocza B, Lahoud OB, Landau HJ, Lin RJ, **Mailankody S**, Palomba ML, Papadopoulos EB, Politikos I, Ponce DM, Sauter CS, Shaffer BC, Scordo M, van den Brink MRM, Perales MA, Tamari R. Cellular therapy during COVID-19: Lessons learned and preparing for subsequent waves. *Transplant and Cell Therapy* 2021; 27(5):438.e1-438.e6. PMID: 33728417.
50. Landgren O, Hultcrantz M, Diamond B, Lesokhin AM, **Mailankody S**, Hassoun H, Tan C, Shah UA, Lu S, Salcedo M, Werner K, Rispoli J, Caple J, Sams A, Verducci D, Jones K, Concepcion I, Ciardello A, Chansakul A, Schlossman J, Tavitian E, Shekarkhand T, Harrison A, Piacentini C, Rustad EH, Yellapantula V, Maclaughlan K, Maura F, Landau HJ, Scordo M, Chung DJ, Shah G, Lahoud OB, Thoren K, Murata K, Ramanathan L, Arcila ME, Ho C, Roshal M, Dogan A, Derkach A, Giralt SA, Korde N. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: The MANHATTAN nonrandomized clinical trial. *JAMA Oncology* 2021;e210611. PMID: 33856405.

[Health policy articles in professional peer-reviewed journals:](#)

1. **Mailankody S**, Prasad V. Comparative effectiveness questions in oncology. *The New England Journal of Medicine* 2014; 370(16): 1478-81. PMID: 24738667.
2. Prasad V, **Mailankody S**. The accelerated approval of oncologic drugs: lessons from ponatinib. *JAMA* 2014; 311(4): 353-4. PMID: 24449310.
3. Prasad V, **Mailankody S**. How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses. *Blood* 2015; 126(15): 1860-1. PMID: 26320099.
4. Prasad V, Kumar H, **Mailankody S**. Ethics of clinical trials in low-resource settings: Lessons from recent trials in cancer medicine. *Journal of Global Oncology* 2015; 2(1):1-3. PMID: 28717675.
5. **Mailankody S**, Prasad V. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies. *The Oncologist* 2016; 21(9): 1031-2. PMID: 27401893.
6. **Mailankody S**, Prasad V. Implications of Proposed Medicare Reforms to Counteract High Cancer Drug Prices. *JAMA* 2016; 316(3): 271-2. PMID: 27149663.
7. Prasad V, **Mailankody S**. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable. *Mayo Clinic Proceedings* 2016; 91(6): 707-12. PMID: 27261866.
8. Prasad V, De Jesus K, **Mailankody S**. A further strategy to combat the high price of anticancer drugs. *Nature Reviews Clinical Oncology* 2017; 14(10): 629. PMID: 28829055.
9. **Mailankody S**, Prasad V. Pharmaceutical marketing for rare diseases: regulating drug company promotion in an era of unprecedented advertisement. *JAMA* 2017; 317(24): 2479-80. PMID: 28520871.
10. **Mailankody S**, Prasad V. Overall survival in cancer drug trials as a new surrogate endpoint for overall survival in the real world. *JAMA Oncology* 2017; 3(7):889-90. PMID: 27892992.
11. Prasad V, Kaestner V, & Mailankody S. Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers. *JAMA Oncology* 2018; 4(2): 157-158. PMID: 29285544.
12. Prasad V, McCabe C, **Mailankody S**. Low-value approvals and high prices might incentivize ineffective drug development. *Nature Reviews Clinical Oncology* 2018; 15(7): 399-400. PMID: 29760505.

#### Reviews and Editorials:

1. **Mailankody S**, Mena E, Yuan CM, Balakumaran A, Kuehl WM, Landgren O. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma. *Leukemia & Lymphoma* 2010; 51(12): 2159-70. PMID: 20958231.
2. Thomas A, **Mailankody S**, Korde N, Kristinsson SY, Turesson I, Landgren O. Second malignancies after multiple myeloma: from 1960s to 2010s. *Blood* 2012; 119(12): 2731-7. PMID: 22310913.
3. **Mailankody S**, Landgren O. HIV, EBV, and Monoclonal Gammopathy. *Blood* 2013; 122(17): 2924-25. PMID: 24159162.
4. Landgren O, **Mailankody S**. Update on second primary malignancies in multiple myeloma: a focused review. *Leukemia* 2014; 28(7): 1423-6. PMID: 24418993.

5. Fojo T, **Mailankody S**, Lo A. Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. *JAMA Otolaryngology-- Head & Neck Surgery* 2014; 140(12): 1225-36. PMID: 25068501.
6. Kazandjian D, **Mailankody S**, Korde N, Landgren O. Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. *Clinical Advances in Hematology & Oncology* 2014; 12(9): 578-87. PMID: 25654479.
7. Korde N, **Mailankody S**, Landgren O. The road to treating smoldering multiple myeloma. *Clinical Lymphoma, Myeloma & Leukemia* 2014; 14 Suppl: S59-64. PMID: 25486957.
8. Manasanch EE, Korde N, **Mailankody S**, Tajeja N, Bhutani M, Roschewski M, Landgren O. Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. *Haematologica* 2014; 99(12): 1769-71. PMID: 25472951.
9. Tajeja N, Manasanch EE, Korde N, Kwok M, **Mailankody S**, Bhutani M, Roschewski M, Landgren O. Smoldering multiple myeloma: present position and potential promises. *European Journal of Haematology* 2014; 92(1): 1-12. PMID: 24112232
10. Ahn IE, **Mailankody S**, Korde N, Landgren O. Dilemmas in treating smoldering multiple myeloma. *Journal of Clinical Oncology* 2015; 33(1): 115-23. PMID: 25422486.
11. **Mailankody S**, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, Landgren O. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. *Nature Reviews Clinical Oncology* 2015; 12(5): 286-95. PMID: 25622976.
12. Vandross, Prasad V, **Mailankody S**. ASCO plenary sessions: impact, legacy, future. *Seminars in Oncology* 2016; 43(3): 321-6. PMID: 27178681.
13. Ahn IE, **Mailankody S**. Controversies in multiple myeloma: Evidence-based update. *Seminars in oncology* 2016; 43(6): 666-75. PMID: 28061984.
14. **Mailankody S**, Landgren O. Monoclonal gammopathy of undetermined significance and Waldenstrom's macroglobulinemia. *Best practice & research Clinical haematology* 2016; 29(2): 187-93. PMID: 27825465.
15. **Mailankody S**. The Affordable Care Act, health insurance coverage and cancer outcomes. *JCO* 2017; 35(35): 3893-3894. PMID: 29035644.
16. Ghosh A, **Mailankody S**, Giralt SA, Landgren CO, Smith EL, Brentjens RJ. CAR T Cell Therapy for Multiple Myeloma: Where Are We Now and Where Are We Headed? *Leukemia & Lymphoma* 2017; pp. 1–12. PMID: 29105517.
17. Prasad V, De Jesus K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. *Nature Reviews Clinical Oncology* 2017; 14(6): 381-390. PMID: 28290490.
18. **Mailankody S**, Bach, P. B. Money-Back Guarantees for Expensive Drugs: Wolfs Clothing but a Sheep Underneath. *Annals of Internal Medicine* 2018; 168(12):888-889. PMID: 29610838.
19. Ganguly S, **Mailankody S**, Ailawadhi S. Many shades of disparities in myeloma care. *ASCO Education Book* 2019; 39: 519-529. PMID: 31099639.
20. Shah UA, **Mailankody S**. CAR T and CAR NK cells in multiple myeloma: Expanding the targets. *Best Practice & Research Clinical Haematology* 2020; 33(1):101141. PMID: 32139020.

21. Shah UA, **Mailankody S**. Emerging immunotherapies in multiple myeloma. British Medical Journal 2020; 370:m3176. PMID: 32958461.

22. Wudhikarn K, **Mailankody S**, Smith EL. Future of CAR T cells in multiple myeloma. Hematology ASH Education Program 2020; 1: 272-279. PMID: 33275747.

#### Chapters:

1. Korde N, **Mailankody S**, Kazandjian D and Landgren O. Multiple Myeloma, The Bethesda Handbook of Clinical Hematology (fourth edition) 2017.

#### Abstracts